Jeffrey Bishop
Psychiatry · Dayton, OHNPI 1811974751
Payments from drug & device makers
Across 147 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$880
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$707
- Otsuka America Pharmaceutical, Inc.$314
- Alkermes, Inc.$168
- Vanda Pharmaceuticals Inc.$126
- Johnson & Johnson$113
- plus $325 from 8 others
What the payments were for
- Food & beverage$2,634100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 52 | $880 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $707 |
| Otsuka America Pharmaceutical, Inc. | 19 | $314 |
| Alkermes, Inc. | 6 | $168 |
| Vanda Pharmaceuticals Inc. | 8 | $126 |
| Johnson & Johnson | 6 | $113 |
| Lundbeck LLC | 6 | $88 |
| Avanir Pharmaceuticals, Inc. | 3 | $54 |
| Teva Pharmaceuticals USA, Inc. | 3 | $49 |
| Eisai Inc. | 3 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $36 |
| AbbVie(2 entities) | 2 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| Tris Pharma Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$128
How this compares
$2,634 in reported general payments places this provider in the 80th percentile of 1,119 psychiatry providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 12 | $42,975 |
| CaplytaLumateperone Tosylate | 13 | $19,204 |
| FetzimaLevomilnacipran Hcl | 12 | $6,055 |
| Quetiapine Fumarate | 149 | $4,109 |
| Oxcarbazepine | 107 | $2,928 |
| Aripiprazole | 75 | $2,554 |
| Clonazepam | 100 | $2,346 |
| Chlorpromazine Hcl | 13 | $2,057 |
| Olanzapine | 54 | $1,754 |
| Amitriptyline Hcl | 75 | $1,530 |
| Atomoxetine Hcl | 13 | $1,316 |
| Risperidone | 53 | $1,312 |
| Doxepin Hcl | 39 | $1,279 |
| Duloxetine Hcl | 88 | $1,274 |
| Alprazolam | 79 | $1,038 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $113 | $42,97512 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $707 | $19,20413 claims |
| AbbVieFetzima | $24 | $6,05512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Dayton
- Otto DuenoDayton$3.1M
- Amita PatelDayton$2.1M
- Richard SandersDayton$1.8M
- Darshan SehbiDayton$137K
- Shishuka MalhotraCanton$15M
- Henry NasrallahCincinnati$3.8M
- Diab AlmhanaAvon Lake$2.7M
- Mohamed Abdel AzizWest Chester$2.6M
- Fred RomeoColumbus$2.3M
- Mark WoyshvilleMiddleburg Heights$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.